BiotechTube

epirubicin + oxaliplatin + capecitabine + zolbetuximab

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

Conditions

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma

Trial Timeline

Jul 19, 2012 → Jan 31, 2019

NCT ID
NCT01630083

About epirubicin + oxaliplatin + capecitabine + zolbetuximab

epirubicin + oxaliplatin + capecitabine + zolbetuximab is a phase 2 stage product being developed by Astellas Pharma for CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction. The current trial status is completed. This product is registered under clinical trial identifier NCT01630083. Target conditions include CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01630083Phase 2Completed

Competing Products

1 competing product in CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

See all competitors
ProductCompanyStageHype Score
IMAB362 + Zoledronic acid + Interleukin-2 (1 million IU) + Interleukin-2 (3 million IU)Astellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85